Biomarkers of Acute Kidney Injury

Advances in Chronic Kidney Disease

Volumn 15, Issue 3, 2008, Pages 222-234

  Edelstein, Charles L ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Acute kidney injury; Biomarkers; Cystatin C; Interleukin 18; Kidney injury molecule 1; Neutrophil gelatinase associated lipocalin

Indexed keywords

BIOLOGICAL MARKER; CREATININE; CYSTATIN C; INTERLEUKIN 18; KIDNEY INJURY MOLECULE 1; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; UREA;

ACUTE KIDNEY FAILURE; ARTICLE; CREATININE BLOOD LEVEL; KIDNEY FUNCTION; KIDNEY INJURY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; UREA NITROGEN BLOOD LEVEL;

BIOLOGICAL MARKERS; HUMANS; KIDNEY; RENAL INSUFFICIENCY, ACUTE;

EID: 44949204503     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2008.04.003     Document Type: Article

References (96)

1. Lassnigg A., Schmidlin D., Mouhieddine M., et al. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: A prospective cohort study. J Am Soc Nephrol 15 (2004) 1597-1605
2. Van Biesen W., Vanholder R., and Lameire N. Defining acute renal failure: RIFLE and beyond. Clin J Am Soc Nephrol 1 (2006) 1314-1319
3. Bellomo R., Kellum J.A., and Ronco C. Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Intensive Care Med 33 (2007) 409-413
4. Waikar S.S., Curhan G.C., Wald R., et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 17 (2006) 1143-1150
5. Lameire N., Van Biesen W., and Vanholder R. The changing epidemiology of acute renal failure. Nat Clin Pract Nephrol 2 (2006) 364-377
6. Stevens L.A., Lafayette R.A., Perrone R.D., et al. Laboratory evaluation of kidney function. In: Schrier R.W. (Ed). Diseases of the Kidney and Urinary Tract. 8th ed (2007), Williams and Wilkins, Philadelphia, PA, Lippincott 299-336
7. Star R.A. Treatment of acute renal failure. Kidney Int 54 (1998) 1817-1831
8. Herget-Rosenthal S., Pietruck F., Volbracht L., et al. Serum cystatin C-A superior marker of rapidly reduced glomerular filtration after uninephrectomy in kidney donors compared to creatinine. Clin Nephrol 64 (2005) 41-46
9. Waikar S.S., and Bonventre J.V. Can we rely on blood urea nitrogen as a biomarker to determine when to initiate dialysis?. Clin J Am Soc Nephrol 1 (2006) 903-904
10. Walser M. Determinants of ureagenesis, with particular reference to renal failure. Kidney Int 17 (1980) 709-721
11. Luke R.G. Uremia and the BUN. N Engl J Med 305 (1981) 1213-1215
12. Shilliday I.R., Quinn K.J., and Allison M.E. Loop diuretics in the management of acute renal failure: A prospective, double-blind, placebo-controlled, randomized study. Nephrol Dial Transplant 12 (1997) 2592-2596
13. Lassnigg A., Donner E., Grubhofer G., Presterl E., et al. Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. J Am Soc Nephrol 11 (2000) 97-104
14. Allgren R.L., Marbury T.C., Rahman S.N., et al. Anaritide in acute tubular necrosis. N Engl J Med 336 (1997) 828-834
15. Lewis J., Salem M.M., Chertow G.M., et al. Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. Am J Kidney Dis 36 (2000) 767-774
16. Hirschberg R., Kopple J., Lipsett P., et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 55 (1999) 2423-2432
17. Kellum J.A. Prophylactic fenoldopam for renal protection? No, thank you, not for me-Not yet at least. Crit Care Med 33 (2005) 2681-2683
18. Moran S.M., and Myers B.D. Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int 27 (1985) 928-937
19. Dinarello C.A. Biologic basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
20. Melnikov V.Y., Ecder T., Fantuzzi G., et al. Impaired IL-18 processing protects caspase-1-deficient mice from ischemic acute renal failure. J Clin Invest 107 (2001) 1145-1152
21. Haq M., Norman J., Saba S.R., et al. Role of IL-1 in renal ischemic reperfusion injury. J Am Soc Nephrol 9 (1998) 614-619
22. Lochner M., and Forster I. Anti-interleukin-18 therapy in murine models of inflammatory bowel disease. Pathobiology 70 (2002) 164-169
23. Pomerantz B.J., Reznikov L.L., Harken A.H., et al. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proc Natl Acad Sci U S A 98 (2001) 2871-2876
24. Hedtjarn M., Leverin A.L., Eriksson K., et al. Interleukin-18 involvement in hypoxic-ischemic brain injury. J Neurosci 22 (2002) 5910-5919
25. Faggioni R., Jones-Carson J., Reed D.A., et al. Leptin-deficient (ob/ob) mice are protected from T cell-mediated hepatotoxicity: Role of tumor necrosis factor alpha and IL-18. Proc Natl Acad Sci U S A 97 (2000) 2367-2372
26. Faggioni R., Cattley R.C., Guo J., et al. IL-18-binding protein protects against lipopolysaccharide-induced lethality and prevents the development of Fas/Fas ligand-mediated models of liver disease in mice. J Immunol 167 (2001) 5913-5920
27. Fiorucci S., Santucci L., Antonelli E., et al. NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines. Gastroenterology 118 (2000) 404-421
28. Plater-Zyberk C., Joosten L.A., Helsen M.M., et al. Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis. J Clin Invest 108 (2001) 1825-1832
29. Dinarello C.A. Novel targets for interleukin 18 binding protein. Ann Rheum Dis 60 suppl 3 (2001) iii18-iii24
30. Dinarello C.A. Interleukin-18 and the treatment of rheumatoid arthritis. Rheum Dis Clin North Am 30 (2004) 417-434
31. Melnikov V.Y., Faubel S.G., Siegmund B., et al. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest 110 (2002) 1083-1091
32. Mehta R.L. Urine IL-18 levels as a predictor of acute kidney injury in intensive care patients. Nat Clin Pract Nephrol 2 (2006) 252-253
33. Parikh C.R., Jani A., Melnikov V.Y., et al. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 43 (2004) 405-414
34. Parikh C.R., Abraham E., Ancukiewicz M., et al. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the ICU. J Am Soc Nephrol 16 (2005) 3046-3052
35. Parikh C.R., Mishra J., Thiessen-Philbrook H., et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 70 (2006) 199-203
36. Parikh C.R., Jani A., Mishra J., et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 6 (2006) 1639-1645
37. Washburn K.K., Zapitelli M., Arikan A.A., et al. Urinary interleukin-18 as an acute kidney injury biomarker in critically ill children. Nephrol Dial Transplant 23 (2008) 566-572
38. Simon T., Opelz G., Wiesel M., et al. Serial peripheral blood interleukin-18 and perforin gene expression measurements for prediction of acute kidney graft rejection. Transplantation 77 (2004) 1589-1595
39. Matsumoto K., and Kanmatsuse K. Elevated interleukin-18 levels in the urine of nephrotic patients. Nephron 88 (2001) 334-339
40. Bulent Gul C., Gullulu M., Oral B., et al. Urinary IL-18: A marker of contrast-induced nephropathy following percutaneous coronary intervention. Clin Biochem 41 (2008) 544-547
41. Schmidt-Ott K.M., Mori K., Li J.Y., et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 18 (2007) 407-413
42. Mishra J., Ma Q., Prada A., et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 14 (2003) 2534-2543
43. Mishra J., Mori K., Ma Q., et al. Neutrophil gelatinase-associated lipocalin: A novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 24 (2004) 307-315
44. Mishra J., Dent C., Tarabishi R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 365 (2005) 1231-1238
45. Dent C., Dastrala S., Bennet M., et al. Plasma NGAL predicts AKI, morbidity and mortality after pediatric cardiac surgery: A prospective uncontrolled cohort study. Crit Care 11 (2007) R127-R132
46. Wagener G., Jan M., Kim M., et al. Association between increases in urinary neutrophil gelatinase-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 105 (2006) 485-491
47. Bachorzewska-Gajewska H., Malyszko J., Sitniewska E., et al. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 26 (2006) 287-292
48. Zapitelli M., Washburn K.K., Arikan A.A., et al. Urine neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in critically ill children: A prospective cohort study. Crit Care 11 (2007) R84
49. Hirsch R., Dent C., Pfriem H., et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 22 (2007) 2089-2095
50. Bolignano D., Coppolino G., Campo S., et al. Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol 27 (2007) 373-378
51. Trachtman H., Christen E., Cnaan A., et al. Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial: Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: A novel marker of renal injury. Pediatr Nephrol 21 (2006) 989-994
52. Suzuki M., Wiers K.M., Klein-Gitelman M.S., et al. Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in lupus nephritis. Pediatr Nephrol 23 (2008) 403-412
53. Ichimura T., Bonventre J.V., Bailly V., et al. Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. J Biol Chem 273 (1998) 4135-4142
54. Vaidya V.S., Ramirez V., Ichimura T., et al. Urinary kidney injury molecule-1: A sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 290 (2006) F517-F529
55. Ichimura T., Hung C.C., Yang S.A., et al. Kidney injury molecule-1: A tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 286 (2004) F552-F563
56. Han W.K., Bailly V., Abichandani R., et al. Kidney injury molecule-1 (KIM-1): A novel biomarker for human renal proximal tubule injury. Kidney Int 62 (2002) 237-244
57. van Timmeren M.M., van den Heuvel M.C., et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. J Pathol 212 (2007) 209-217
58. Zhang P.L., Rothblum L.I., Han W.K., et al. Kidney injury molecule-1 expression in transplant biopsies is a sensitive measure of cell injury. Kidney Int 73 (2008) 608-614
59. van Timmeren M.M., Vaidya V.S., van Ree R.M., et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation 84 (2007) 1625-1630
60. Liangos O., Perianayagam M.C., Vaidya V.S., et al. Urinary N-Acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol 18 (2007) 904-912
61. Uzun H., Ozmen K.M., Ataman R., et al. Serum cystatin C level as a potentially good marker for impaired kidney function. Clin Biochem 38 (2005) 792-798
62. Hartmann H.G., Braedel H.E., and Jutzler G.A. Detection of renal tubular lesions after abdominal aortography and selective renal arteriography by quantitative measurements of brush-border enzymes in the urine. Nephron 39 (1985) 95-101
63. Herget-Rosenthal S., Poppen D., Husing J., et al. Prognostic value of tubular proteinuria and enzymuria in nonoliguric acute tubular necrosis. Clin Chem 50 (2004) 552-558
64. Blaikley J., Sutton P., Walter M., et al. Tubular proteinuria and enzymuria following open heart surgery. Intensive Care Med 29 (2003) 1364-1367
65. Fink J.C., Cooper M.A., and Zager R.A. Hemodialysis exacerbates enzymuria in patients with acute renal failure: Brief report. Ren Fail 18 (1996) 947-950
66. Sarvary E., Borka P., Sulyok B., et al. Diagnostic value of urinary enzyme determination in renal transplantation. Transplant Int 9 suppl 1 (1996) S68-S72
67. Westhuyzen J., Endre Z.H., Reece G., et al. Measurement of tubular enzymuria facilitates early detection of acute renal impairment in the intensive care unit. Nephrol Dial Transplant 18 (2003) 543-551
68. Butler F.A., and Flynn F.V. The occurrence of post-gamma protein in urine: A new protein abnormality. J Clin Pathol 14 (1961) 172-178
69. Westhuyzen J. Cystatin C: A promising marker and predictor of impaired renal function. Ann Clin Lab Sci 36 (2006) 387-394
70. Simonsen O., Grubb A., and Thysell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 45 (1985) 97-101
71. Grubb A., Nyman U., Bjork J., et al. Simple cystatin C-based prediction equations for glomerular filtration rate compared with the modification of diet in renal disease prediction equation for adults and the Schwartz and the Counahan-Barratt prediction equations for children. Clin Chem 51 (2005) 1420-1431
72. Artunc F.H., Fischer I.U., Risler T., et al. Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catheterization. Int J Cardiol 102 (2005) 173-178
73. Filler G., Bokenkamp A., Hofmann W., et al. Cystatin C as a marker of GFR-History, indications, and future research. Clin Biochem 38 (2005) 1-8
74. Orlando R., Mussap M., Plebani M., et al. Diagnostic value of plasma cystatin C as a glomerular filtration marker in decompensated liver cirrhosis. Clin Chem 48 (2002) 850-858
75. Herget-Rosenthal S., Marggraf G., Husing J., et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 66 (2004) 1115-1122
76. Villa P., Jimenez M., Soriano M.C., et al. Serum cystatin C concentration as a marker of acute renal dysfunction in critically ill patients. Crit Care 9 (2005) R139-R143
77. Baas M.C., Bouman C.S., Hoek F.J., et al. Cystatin C in critically ill patients treated with continuous venovenous hemofiltration. Hemodial Int 10 suppl 2 (2006) S33-S37
78. Manetti L., Pardini E., Genovesi M., et al. Thyroid function differently affects serum cystatin C and creatinine concentrations. J Endocrinol Invest 28 (2005) 346-349
79. Risch L., Herklotz R., Blumberg A., et al. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 47 (2001) 2055-2059
80. Risch L., and Huber A.R. Glucocorticoids and increased serum cystatin C concentrations. Clin Chim Acta 320 (2002) 133-134
81. Knight E.L., Verhave J.C., Spiegelman D., et al. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 65 (2004) 1416-1421
82. Shlipak M.G., Sarnak M.J., Katz R., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352 (2005) 2049-2060
83. Jernberg T., Lindahl B., James S., et al. Cystatin C: A novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 110 (2004) 2342-2348
84. Herget-Rosenthal S., Bokenkamp A., and Hofmann W. How to estimate GFR-serum creatinine, serum cystatin C or equations?. Clin Biochem 40 (2007) 153-161
85. Han W.K., Waikar S.S., Johnson A., et al. Urinary biomarkers in the early diagnosis of acute kidney injury. Kidney Int 73 (2008) 863-869
86. Mori K., Lee H.T., Rapoport D., et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 115 (2005) 610-621
87. Hofmeister R., Bhargava A.S., and Gunzel P. Value of enzyme determinations in urine for the diagnosis of nephrotoxicity in rats. Clin Chim Acta 160 (1986) 163-167
88. Holly M.K., Dear J.W., Hu X., et al. Biomarker and drug-target discovery using proteomics in a new rat model of sepsis-induced acute renal failure. Kidney Int 70 (2006) 496-506
89. du Cheyron D., Daubin C., Poggioli J., et al. Urinary measurement of Na+/H+ exchanger isoform 3 (NHE3) protein as new marker of tubule injury in critically ill patients with ARF. Am J Kidney Dis 42 (2003) 497-506
90. Muramatsu Y., Tsujie M., Kohda Y., et al. Early detection of cysteine rich protein 61 (CYR61, CCN1) in urine following renal ischemic reperfusion injury. Kidney Int 62 (2002) 1601-1610
91. Fujisaki K., Kubo M., Masuda K., et al. Infusion of radiocontrast agents induces exaggerated release of urinary endothelin in patients with impaired renal function. Clin Exp Nephrol 7 (2003) 279-283
92. Taman M., Liu Y., Tolbert E., et al. Increase urinary hepatocyte growth factor excretion in human acute renal failure. Clinical Nephrol 48 (1997) 241-245
93. Iglesias J., Marik P.E., Levine J.S., et al. I: Elevated serum levels of the type I and type II receptors for tumor necrosis factor-alpha as predictive factors for ARF in patients with septic shock. Am J Kidney Dis 41 (2003) 62-75
94. Marcussen N., Schumann J., Campbell P., et al. Cytodiagnostic urinalysis is very useful in the differential diagnosis of acute renal failure and can predict the severity. Ren Fail 17 (1995) 721-729
95. Kwon O., Molitoris B.A., Pescovitz M., et al. Urinary actin, interleukin-6, and interleukin-8 may predict sustained ARF after ischemic injury in renal allografts. Am J Kidney Dis 41 (2003) 1074-1087
96. Portilla D., Dent C., Sugaya T., et al. Liver fatty acid binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 73 (2008) 465-472